All In Biotech

Drug Trial Radar · NCT07085767

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Nov 3, 2025

Primary completion

Dec 2028

Study completion Jan 2032

Sponsor

Lead sponsor
Olema Oncology, Inc.Industry
Sponsor type
Industry
Collaborators
Novartis Pharmaceuticals
First posted
Jul 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Conditions

  • Breast Cancer
  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer
  • ER Positive Breast Cancer
  • HER2 Negative Breast Carcinoma

Interventions

  • PalazestrantDrug

    Participants will be treated with palazestrant 90 mg once daily on a 4-week (28-day) cycle.

  • Letrozole-matching placeboDrug

    Participants will be treated with letrozole-matching placebo once daily on a 4-week (28 day) cycle

  • RibociclibDrug

    Participants will be treated with ribociclib 600 mg once daily on Days 1-21 of a 4-week (28 day) cycle.

  • LetrozoleDrug

    Participants will be treated with letrozole 2.5 mg once daily on a 4-week (28-day) cycle

  • Palazestrant matching-placeboDrug

    Participants will be treated with palazestrant-matching placebo once daily on a 4-week (28-day) cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (estimated as up to 3.5 years)

Locations

200 sites in 23 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Hot Springs, Arkansas · Recruiting

  • Clinical Trial Site

    Beverly Hills, California · Recruiting

  • Clinical Trial Site

    La Jolla, California · Recruiting

  • Clinical Trial Site

    Los Alamitos, California · Recruiting

  • Clinical Trial Site

    Oakland, California · Recruiting

  • Clinical Trial Site

    Roseville, California · Recruiting

  • Clinical Trial Site

    San Francisco, California · Recruiting

  • Clinical Trial Site

    San Francisco, California · Recruiting

  • Clinical Trial Site

    Santa Barbara, California · Recruiting

  • Clinical Trial Site

    Santa Clara, California · Recruiting

  • Clinical Trial Site

    Vallejo, California · Recruiting

  • Clinical Trial Site

    Walnut Creek, California · Recruiting

  • Clinical Trial Site

    Aurora, Colorado · Recruiting

  • Clinical Trial Site

    Denver, Colorado · Recruiting

  • Clinical Trial Site

    New Haven, Connecticut · Recruiting

  • Clinical Trial Site

    Tampa, Florida · Recruiting

  • Clinical Trial Site

    Marietta, Georgia · Recruiting

  • Clinical Trial Site

    Honolulu, Hawaii · Recruiting

  • Clinical Trial Site

    Peoria, Illinois · Recruiting

  • Clinical Trial Site

    Urbana, Illinois · Recruiting

  • Clinical Trial Site

    Ames, Iowa · Withdrawn

  • Clinical Trial Site

    Scarborough, Maine · Recruiting

  • Clinical Trial Site

    Annapolis, Maryland · Recruiting

  • Clinical Trial Site

    Baltimore, Maryland · Recruiting

  • Clinical Trial Site

    Baltimore, Maryland · Recruiting

  • Clinical Trial Site

    Catonsville, Maryland · Recruiting

  • Clinical Trial Site

    Burlington, Massachusetts · Recruiting

  • Clinical Trial Site

    Ann Arbor, Michigan · Recruiting

  • Clinical Trial Site

    Minneapolis, Minnesota · Recruiting

  • Clinical Trial Site

    Jackson, Mississippi · Recruiting

  • Clinical Trial Site

    Kansas City, Missouri · Recruiting

  • Clinical Trial Site

    Lebanon, New Hampshire · Recruiting

  • Clinical Trial Site

    Santa Fe, New Mexico · Recruiting

  • Clinical Trial Site

    New York, New York · Recruiting

  • Clinical Trial Site

    New York, New York · Recruiting

  • Clinical Trial Site

    Charlotte, North Carolina · Recruiting

  • Clinical Trial Site

    Durham, North Carolina · Recruiting

  • Clinical Trial Site

    Cincinnati, Ohio · Recruiting

  • Clinical Trial Site

    Columbus, Ohio · Recruiting

  • Clinical Trial Site

    Columbus, Ohio · Recruiting

Showing 40 of 200 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.